In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Daiichi buys Plexxikon for $805mm up front, plus earn-outs

Executive Summary

Daiichi Sankyo Co. Ltd. will pay $805mm in cash to acquire privately held drug discovery company Plexxikon Inc., a move that will greatly expand the Japanese pharmaco's oncology business. The deal has also been sweetened with up to $130mm in launch-related earn-outs based on PLX4032, Plexxikon's lead candidate for malignant melanoma.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash for Equity

Related Companies